Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy
Launched by UNIVERSITY OF MICHIGAN · Oct 23, 2017
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
For infants and newborns who have a heart defect at birth that leaves them with one functional ventricle, there is a series of surgeries that are required to allow survival. These surgeries ultimately lead to a common heart and great blood vessel circulation called a cavopulmonary anastomosis (Fontan). This has allowed for survival into adulthood from universally fatal outcome in infancy. However, the non-physiologic blood flow patterns of the Fontan pathway do result in certain complications, including protein losing enteropathy (PLE), which occurs in 3.7-13.4% of patients. PLE is denoted ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males and females with Fontan physiology of any age
- • Must have protein losing enteropathy with current worsening who require additional therapies
- • Participant consent or parental/guardian consent and participant assent
- Exclusion Criteria:
- • Patients with inflammatory bowel disease (i.e Crohn's, ulcerative colitis)
- • Patients with systemic autoimmune disease (i.e. Systemic Lupus Erythematous)
- • Patients with primary immunodeficiency syndromes
- • Patients with nephrotic syndrome
- • Patients with anemia
- • Patients less than 31 pounds
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Kurt Schumacher, MD, MS
Principal Investigator
University of Michigan Division of Pediatric Cardiology
Joshua Meisner, MD, PhD
Principal Investigator
University of Michigan Division of Pediatric Cardiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials